Christian Riklin

Establishing the Swiss Spinal Tumor Registry (Swiss-STR): a prospective observation of surgical treatment patterns and long-term outcomes in patients with primary and metastatic spinal tumors

Edin Nevzati, Nicolas Poletti, Alexander Spiessberger, Sabrina Bäbler et autres

Background: Tumors of the vertebral column consist of primary spinal tumors and malignancies metastasizing to the spine. Although primary spine tumors are rare, metastases to the spine have gradually increased over past decades because of aging populations and improved survival for various …

ch, us (code pays fourni par la source)

«Less is more» pour les traitements médicamenteux des cancers

Magdalena Hecz, Stefan Paul Aebi, Beat Mller, Thilo Zander et autres

Les progrès réalisés dans les traitements médicamenteux des cancers sont considérables et importants, mais ils comportent aussi le risque d’un surtraitement. La campagne «choosing wisely» et le principe «less is more» gagnent en importance.

ch (code pays fourni par la source)

«Less is more» bei medikamentösen Tumortherapien

Magdalena Hecz, Stefan Paul Aebi, Beat Mller, Thilo Zander et autres

Der Fortschritt bei medikamentösen Tumortherapien ist gross und wichtig, birgt aber auch die Gefahr von Überbehandlung. «Choosing wisely» und das Prinzip «less is more» gewinnen zunehmend auch in der Onkologie an Bedeutung.

ch, us (code pays fourni par la source)

Swiss experience of atezolizumab for platinum-pretreated urinary tract carcinoma: the SAUL study in real-world practice

Richard L. Cathomas, Julian Schardt, Miklos Pless, Anna Lladó et autres

AIMS OF THE STUDY: Atezolizumab is an approved therapy for urothelial carcinoma based on results from the IMvigor 210 and IMvigor211 phase II and III trials. The global SAUL study evaluated atezolizumab in a broader patient population more representative of real-world populations. …

ch (code pays fourni par la source)

Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial

Hans‐Georg Wirsching, Ghazaleh Tabatabai, Ulrich Roelcke, Andreas Felix Hottinger et autres

Background: The addition of bevacizumab to temozolomide-based chemoradiotherapy (TMZ/RT → TMZ) did not prolong overall survival (OS) in patients with newly diagnosed glioblastoma in phase III trials. Elderly and frail patients are underrepresented in clinical trials, but early reports suggested preferential benefit …

ch, de (code pays fourni par la source)

ACTR-05. THE RANDOMIZED PHASE II ARTE TRIAL: BEVACIZUMAB PLUS HYPOFRACTIONATED RADIOTHERAPY VERSUS RADIOTHERAPY ALONE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

Michael Weller, Ghazaleh Tabatabai, Ulrich Roelcke, Andreas Felix Hottinger et autres

The addition of bevacizumab to temozolomide-based chemoradiotherapy (TMZ/RT→TMZ) prolonged progression-free survival (PFS), but not overall survival (OS) in patients with newly diagnosed glioblastoma in two double-blind phase III trials. Elderly and frail patients are underrepresented in most clinical trials, but early reports …

ch, de (code pays fourni par la source)

Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: Efficacy and imaging analyses of the ARTE trial.

Hans‐Georg Wirsching, Ghazaleh Tabatabai, Ulrich Roelcke, Andreas Felix Hottinger et autres

2014 Background: The addition of bevacizumab (BEV) to first-line temozolomide chemoradiotherapy prolonged progression-free survival (PFS), but not overall survival (OS) in newly diagnosed glioblastoma in two phase III trials. Elderly and frail patients are underrepresented in most clinical trials, but early uncontrolled …

ch (code pays fourni par la source)

BRAF V600E mutation: A treatable driver mutation in pleomorphic xanthoastrocytoma (PXA)

Silvia Höfer, Grégoire Berthod, Christian Riklin, Elisabeth Jane Rushing et autres

BRAF V600E mutations have therapeutic implications in a wider range of tumors than previously considered. Anaplastic pleomorphic xanthoastrocytoma (PXA), a rare tumor entity, accounts for less than...

ch (code pays fourni par la source)

Comparison of 18F-FDG PET/CT and 68Ga-DOTATATE PET/CT Imaging in Metastasized Merkel Cell Carcinoma

Maximilian Epstude, Katharina Tornquist, Christian Riklin, Francesca di Lenardo et autres

Merkel cell carcinoma (MCC) is a rare but very aggressive neuroendocrine tumor of the skin in elderly patients with higher mortality compared with melanoma. No evidence-based standardized chemotherapy exists for metastasized patients.We report the case of an 87-year-old patient with the history …

ch (code pays fourni par la source)

Experience in Integrating ALK Testing and Crizotinib into the Routine Treatment of Patients with Non-Small Cell Lung Cancer

Oliver Pascal Gautschi, Hubert Schefer, Christian Riklin, Klaus Strobel et autres

BACKGROUND: Crizotinib, an inhibitor of the anaplastic lymphoma kinase (ALK), is approved since 2012 in Switzerland for use in ALK-rearranged advanced pretreated non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Here we describe our own experience with crizotinib and ALK testing via …

ch, cl (code pays fourni par la source)

PharmaNews / Ticker

Ulrich Richard Kleeberg, Michael Anthony Fink, Hans-Werner Tessen, Alice Nennecke et autres

PharmaForum

Ulrich Richard Kleeberg, Michael Anthony Fink, Hans-Werner Tessen, Alice Nennecke et autres